| Literature DB >> 32039172 |
Heidi J Mitchell1, Detlef Bartsch2.
Abstract
Invasive species can cause significant harm to the environment, agriculture, and human health, but there are often very limited tools available to control their populations. Gene drives (GD) have been proposed as a new tool which could be used to control or eliminate such species. Here, GD describes a variety of molecular biology applications which all enable the introduction of genetic elements at a higher than expected frequency. These elements can change the genotypes in target populations rapidly with consequences either for (intrinsic) fitness or host-parasite interaction, or both. Beneficial applications are foreseen for human and animal health, agriculture, or nature conservation. This rapidly developing technology is likely to have major impacts in the fight against various diseases, pests, and invasive species. The majority of GD applications involve genetic engineering and novel traits. Therefore, applicants and GMO regulators need to interact to achieve the benefits in innovation while cautiously avoiding unacceptable risks. The release into the environment may include transboundary movement and replacement of target populations, with potential impact on human/animal health and the environment. This article summarizes knowledge-based discussions to identify information gaps and analyzes scenarios for responsible introduction of GD organisms into the environment. It aims to connect the latest scientific developments with regulatory approaches and decision-making.Entities:
Keywords: environmental risk assessment (ERA); gene drive; genome editing; invasive species; regulation
Year: 2020 PMID: 32039172 PMCID: PMC6985037 DOI: 10.3389/fbioe.2019.00454
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
Figure 1The “four-leaf clover” of innovation. The model is derived from the Theory of Culture Development (altered from Figure 4 of von Thienen et al., 2019). Innovation depends on the requirement of all four leaf branches. Three of them (white letters) evolve directly from [human] culture. Novel needs [including environmental protection goals] based on human values (1) which are only viable if [economic] business (2) is possible in combination with the development of novel [technology] designs (3). As an indirect driver, encouragement by regulation (4) completes the successful leaf development.
International legal frameworks (adapted with permission from Redford et al., 2019).
| Convention on Biological Diversity (CBD) Adopted: 1992, Entered into force: 1993 Parties: 196 | Global legal framework addressing conservation, sustainable use and sharing of benefits of biodiversity | Creates obligations for each Party to manage risks associated with living modified organisms that could have a negative impact on biological diversity [art. 8(g)] and framework for access and benefit sharing relating to genetic resources (art. 15). |
| Cartagena Protocol on Biosafety to the Convention on Biological Diversity (Cartagena Protocol) Adopted: 2000, Entered into force: 2003 Parties: 171 | Protocol to CBD intended to ensure the “safe transfer, handling and use of living modified organisms resulting from modern biotechnology that may have adverse effects on biological diversity…” (art. 1) | Requires sharing of risk related information between exporting and importing Parties and provides guidelines on methodology for environmental risk assessments and considerations in decision-making. |
| Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress to the Cartagena Protocol on Biosafety (Supplementary Protocol) Adopted: 2010, Entered into force: 2018 Parties: 42 | Supplementary Protocol to Cartagena Protocol intended to provide rules and procedures for liability and redress relating to living modified organisms | Provides for national frameworks requiring response measures and assigning civil liability in event of damage resulting from living modified organisms which find their origin in transboundary movement. |
| Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity (Nagoya Protocol) Adopted: 2010, Entered into force/not entered into force | Protocol to CBD providing international framework for access to genetic resources and sharing of benefits arising from their utilization | Applies to genetic resources that serve as source material for synthetic biology research. Creates ABS framework based on traceability and transfer of material. |
Figure 2The six steps in the analysis of Environmental Risk Assessment (ERA) in the European Union according to Directive 2001/18/EC (EC—European Commission, 2001).
Figure 3Structure of the EFSA Guidance document on ERA of GM animals, which would apply to GD insects. In late 2018, EFSA received a new mandate from the EU Commission on GMOs engineered with gene drives (gene drive modified organisms) and their implications for RA methodologies. EFSA is requested to identify potential risks in terms of impact on human and animal health and the environment. EFSA is also asked to identify potential novel hazards and to determine whether the existing guidelines are adequate or whether there is a need for updated guidance. EFSA is not requested to develop guidelines for the RA of gene drive modified organisms. Thus, the current guidance on the ERA of GM plants and animals are still valid (EFSA Panel on Genetically Modified Organisms., 2010, 2013).